Baidu
map

Glia:NF-Y调控网络调节少突胶质细胞中谷氨酸受体4的表达

2018-05-11 cuiguizong MedSci原创

英国伯明翰大学医学和牙科学院的神经科学与眼科研究组的Begum G近日在Glia发表了一篇文章,他们发现,CCAAT结合转录因子NF-Yb是Gria4(GluA4基因)的新型转录调节因子,并且是少突胶质细胞中兴奋性毒性死亡的关键调控因子。

英国伯明翰大学医学和牙科学院的神经科学与眼科研究组的Begum G近日在Glia发表了一篇文章,他们发现,CCAAT结合转录因子NF-Yb是Gria4(GluA4基因)的新型转录调节因子,并且是少突胶质细胞中兴奋性毒性死亡的关键调控因子。

对兴奋性毒性敏感的神经细胞高度表达谷氨酸受体亚基4(GluA4)。少突胶质细胞前体细胞(OPC)在缺氧缺血性损伤的关键时期表达水平较高。因此,研究兴奋性GluA4激活的下游转录网络对干预治疗是有希望的。

他们发现,Gria4包含CCAAT序列的区域是一个新调控区域,与NF-Yb的结合受兴奋性因子的调节。NF-Yb结合引起的兴奋性改变与Gria4转录水平改变相关,而敲低NF-Yb的水平可以导致含有该调节区域转录水平的变化。永生化和原代OPC细胞实验数据揭示,通过RNAi的方法和使用NF-Yb药理学破坏,都可以改变Gria4的转录水平。NF-Yb药物可以诱导细胞凋亡并影响一组凋亡基因的表达。

这些数据首次揭示了调控Gria4的反式作用机制,并指出NF-Yb调控网络是促进少突胶质细胞前体细胞存活的药理学潜在靶点。

原文出处:

Begum, G., et al., NF-Y-dependent regulation of glutamate receptor 4 expression and cell survival in cells of the oligodendrocyte lineage. Glia, 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1718483, encodeId=2ede1e1848342, content=<a href='/topic/show?id=8c9c4e23313' target=_blank style='color:#2F92EE;'>#少突胶质细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47233, encryptionId=8c9c4e23313, topicName=少突胶质细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19e332575954, createdName=liuquan, createdTime=Wed Nov 21 19:15:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041068, encodeId=c5ea20410685f, content=<a href='/topic/show?id=24b49216146' target=_blank style='color:#2F92EE;'>#谷氨酸受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92161, encryptionId=24b49216146, topicName=谷氨酸受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue May 22 04:15:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009975, encodeId=2ebb20099e587, content=<a href='/topic/show?id=8ea392018c9' target=_blank style='color:#2F92EE;'>#调控网络#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92018, encryptionId=8ea392018c9, topicName=调控网络)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Thu Aug 16 07:15:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389194, encodeId=7148138919479, content=<a href='/topic/show?id=acf3840e459' target=_blank style='color:#2F92EE;'>#胶质细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84074, encryptionId=acf3840e459, topicName=胶质细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/DC48AC6B5FFD609EED5594C15A97B420/100, createdBy=57dc2500034, createdName=ms1692212821629096, createdTime=Sun May 13 04:15:00 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=314152, encodeId=182b314152b5, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri May 11 13:37:11 CST 2018, time=2018-05-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1718483, encodeId=2ede1e1848342, content=<a href='/topic/show?id=8c9c4e23313' target=_blank style='color:#2F92EE;'>#少突胶质细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47233, encryptionId=8c9c4e23313, topicName=少突胶质细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19e332575954, createdName=liuquan, createdTime=Wed Nov 21 19:15:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041068, encodeId=c5ea20410685f, content=<a href='/topic/show?id=24b49216146' target=_blank style='color:#2F92EE;'>#谷氨酸受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92161, encryptionId=24b49216146, topicName=谷氨酸受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue May 22 04:15:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009975, encodeId=2ebb20099e587, content=<a href='/topic/show?id=8ea392018c9' target=_blank style='color:#2F92EE;'>#调控网络#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92018, encryptionId=8ea392018c9, topicName=调控网络)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Thu Aug 16 07:15:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389194, encodeId=7148138919479, content=<a href='/topic/show?id=acf3840e459' target=_blank style='color:#2F92EE;'>#胶质细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84074, encryptionId=acf3840e459, topicName=胶质细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/DC48AC6B5FFD609EED5594C15A97B420/100, createdBy=57dc2500034, createdName=ms1692212821629096, createdTime=Sun May 13 04:15:00 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=314152, encodeId=182b314152b5, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri May 11 13:37:11 CST 2018, time=2018-05-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1718483, encodeId=2ede1e1848342, content=<a href='/topic/show?id=8c9c4e23313' target=_blank style='color:#2F92EE;'>#少突胶质细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47233, encryptionId=8c9c4e23313, topicName=少突胶质细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19e332575954, createdName=liuquan, createdTime=Wed Nov 21 19:15:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041068, encodeId=c5ea20410685f, content=<a href='/topic/show?id=24b49216146' target=_blank style='color:#2F92EE;'>#谷氨酸受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92161, encryptionId=24b49216146, topicName=谷氨酸受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue May 22 04:15:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009975, encodeId=2ebb20099e587, content=<a href='/topic/show?id=8ea392018c9' target=_blank style='color:#2F92EE;'>#调控网络#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92018, encryptionId=8ea392018c9, topicName=调控网络)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Thu Aug 16 07:15:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389194, encodeId=7148138919479, content=<a href='/topic/show?id=acf3840e459' target=_blank style='color:#2F92EE;'>#胶质细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84074, encryptionId=acf3840e459, topicName=胶质细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/DC48AC6B5FFD609EED5594C15A97B420/100, createdBy=57dc2500034, createdName=ms1692212821629096, createdTime=Sun May 13 04:15:00 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=314152, encodeId=182b314152b5, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri May 11 13:37:11 CST 2018, time=2018-05-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1718483, encodeId=2ede1e1848342, content=<a href='/topic/show?id=8c9c4e23313' target=_blank style='color:#2F92EE;'>#少突胶质细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47233, encryptionId=8c9c4e23313, topicName=少突胶质细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19e332575954, createdName=liuquan, createdTime=Wed Nov 21 19:15:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041068, encodeId=c5ea20410685f, content=<a href='/topic/show?id=24b49216146' target=_blank style='color:#2F92EE;'>#谷氨酸受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92161, encryptionId=24b49216146, topicName=谷氨酸受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue May 22 04:15:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009975, encodeId=2ebb20099e587, content=<a href='/topic/show?id=8ea392018c9' target=_blank style='color:#2F92EE;'>#调控网络#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92018, encryptionId=8ea392018c9, topicName=调控网络)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Thu Aug 16 07:15:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389194, encodeId=7148138919479, content=<a href='/topic/show?id=acf3840e459' target=_blank style='color:#2F92EE;'>#胶质细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84074, encryptionId=acf3840e459, topicName=胶质细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/DC48AC6B5FFD609EED5594C15A97B420/100, createdBy=57dc2500034, createdName=ms1692212821629096, createdTime=Sun May 13 04:15:00 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=314152, encodeId=182b314152b5, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri May 11 13:37:11 CST 2018, time=2018-05-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1718483, encodeId=2ede1e1848342, content=<a href='/topic/show?id=8c9c4e23313' target=_blank style='color:#2F92EE;'>#少突胶质细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47233, encryptionId=8c9c4e23313, topicName=少突胶质细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19e332575954, createdName=liuquan, createdTime=Wed Nov 21 19:15:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041068, encodeId=c5ea20410685f, content=<a href='/topic/show?id=24b49216146' target=_blank style='color:#2F92EE;'>#谷氨酸受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92161, encryptionId=24b49216146, topicName=谷氨酸受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Tue May 22 04:15:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009975, encodeId=2ebb20099e587, content=<a href='/topic/show?id=8ea392018c9' target=_blank style='color:#2F92EE;'>#调控网络#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92018, encryptionId=8ea392018c9, topicName=调控网络)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Thu Aug 16 07:15:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389194, encodeId=7148138919479, content=<a href='/topic/show?id=acf3840e459' target=_blank style='color:#2F92EE;'>#胶质细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84074, encryptionId=acf3840e459, topicName=胶质细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/DC48AC6B5FFD609EED5594C15A97B420/100, createdBy=57dc2500034, createdName=ms1692212821629096, createdTime=Sun May 13 04:15:00 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=314152, encodeId=182b314152b5, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri May 11 13:37:11 CST 2018, time=2018-05-11, status=1, ipAttribution=)]
    2018-05-11 1ddf0692m34(暂无匿称)

    学习了.长知识

    0

相关资讯

江苏省医学会眼科分会第二次白内障专题研讨会

江苏省医学会眼科分会第二次白内障专题研讨会暨镇江市眼科疾病诊疗进展学习班于20184.27-4.29召开。

盘点:眼科研究新进展

1. 眼科临床基础研究 Curr Eye Res:视网膜脱离和增殖性玻璃体视网膜病变中抗视网膜抗体的水平 日本仙台东北大学医学研究院眼科的Ichinohasama R近日在Curr Eye Res发表了一项工作,他们研究了眼内抗视网膜抗体与孔源性视网膜脱离(RRD)和增殖性玻璃体视网膜病变(PVR)患者的临床测量之间的相关性。 抗视网膜抗体和IgG水平相互关联(P <

Optom Vis Sci:荧光素血管造影适应症

西班牙IOBA的Labrador-Velandia SC近日在Optom Vis Sci发表了一项工作,他们对光学相干断层扫描(OCT)和抗血管内皮生长因子(抗VEGF)治疗植入前后荧光素血管造影的检查频率和适应症进行了研究。这些研究提供了有关三级医院进行荧光素血管造影检查指征变化的定量数据。在文章中,他们总结了超过10年的所有关于血管造影研究的详尽数据,包括诊断、首次随访、与抗血管生成剂可能的关

盘点:眼科药物及临床治疗研究进展

1. 眼科临床药物研究 Am J Epidemiol:用阿奇霉素治疗沙眼与衣原体ompA多样性之间的关系 加利福尼亚大学旧金山分校的Chin SA近日在Am J Epidemiol发表了一篇文章,他们对大规模使用阿奇霉素导致衣原体遗传多样性降低,并有可能再次导致感染复发的假设进行研究,最终认为其证据不支持ompA多样性与眼睛衣原体传播有关。 先前的研究已经预测到,针对沙眼治疗大规模的

祝贺!诺华重磅眼科新药诺适得®在中国获批

诺华制药(中国)宣布,诺适得®(雷珠单抗)获国家药品监督管理局批准用于治疗继发于视网膜静脉阻塞(RVO),包括视网膜分支静脉阻塞(BRVO)或视网膜中央静脉阻塞(CRVO)的黄斑水肿引起的视力损害,成为中国目前唯一具有视网膜静脉阻塞适应症的抗VEGF药物。视网膜静脉阻塞是由于视网膜静脉血栓形成而造成的,是第二常见的视网膜血管性疾病[1]。RVO在世界范围内影响约1600万人,因RVO继发的黄斑水肿

成都眼科医生消化道出血1000毫升,咬牙做完4台手术昏倒

这是一位“铁人”医生的故事。51岁的眼科医生廖晓波,站上了手术台,接连4台高龄老人的白内障手术等着他。上手术台前,腹痛已经袭来,廖晓波不太顾得上。每台手术从准备到完毕,需要40分钟。他想专心干好这160分钟。咬牙坚持完最后一台手术,他已腹痛难忍,昏倒在手术室。此时,他消化道大出血,已经达到1000ml,十分危急!咬牙撑完4台手术,“铁人”医生倒在手术台在四川都江堰,找廖主任看眼睛,是群众很信任的

Baidu
map
Baidu
map
Baidu
map